Amneal Pharmaceuticals
AMRX
277 hedge funds and large institutions have $1.95B invested in Amneal Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 100 increasing their positions, 80 reducing their positions, and 25 closing their positions.
611% more call options, than puts
Call options by funds: $7.01M | Put options by funds: $985K
128% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 25
29% more capital invested
Capital invested by funds: $1.51B → $1.95B (+$437M)
25% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 80
12% more funds holding
Funds holding: 248 → 277 (+29)
1.15% more ownership
Funds ownership: 48.01% → 49.17% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
Top Buyers
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$18.4M |
| 2 |
Morgan Stanley
New York
|
+$15M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$12.7M |
| 4 |
D.E. Shaw & Co
New York
|
+$12.5M |
| 5 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$11.5M |
Top Sellers
AMRX Hedge Fund Activity: Q4 2025 in Review
277 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q4 2025, worth a combined $1.95B — up 29% from $1.51B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new AMRX positions and 25 closed out — a net gain of 32 holders — while 100 added to existing stakes and 80 trimmed.
The largest buyer was Assenagon Asset Management, adding an estimated $18.4M. The largest seller was Nantahala Capital Management, cutting an estimated $20.3M.
- 277 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q4 2025, up from 248 in Q3 2025.
- Funds reported $1.95B of Amneal Pharmaceuticals stock for Q4 2025, up 29% quarter-over-quarter.
- 57 funds opened new Amneal Pharmaceuticals positions in Q4 2025 and 25 closed out, a net change of +32 holders.
- The largest Amneal Pharmaceuticals buyer in Q4 2025 was Assenagon Asset Management, an estimated $18.4M added.
- The largest Amneal Pharmaceuticals seller in Q4 2025 was Nantahala Capital Management, an estimated $20.3M sold.
Based on aggregated 13F filings for Q4 2025.